In 2015-16, 12 study sites are participating in the primary care I-MOVE+ multicentre case-control study: Croatia, Germany, France, Hungary, Ireland, Italy, Poland, Portugal, Romania, Spain, Sweden (not funded through H2020) and the Netherlands, We measure influenza VE against medically-attended laboratory confirmed influenza using a test-negative design as described in the I-MOVE+ and I-MOVE generic protocols and in the I-MOVE multicentre case-control publications. We present below the 2015-16 interim estimates (week 41/2015 - week 3/2016) including the results in the 65+ years (target population of I-MOVE+) and in the other age groups. Romania and Croatia are not included as at the time of the analysis, there were no influenza positive cases in their studies. The 2015-16 season started late in the participating countries. Therefore, the sample size for this interim analysis was limited resulting in low precision. The results should be interpreted with caution. The final estimates will be available at the end of the influenza season. Table: Influenza vaccine effectiveness against medically-attended laboratory confirmed influenza by influenza type/suptype, overall and in the age group 18-64 years. I-MOVE/I-MOVE+ multicentre case control study, interim results influenza season 2015-16 (week 41/2015-week 3/2016).
* VE Vaccine effectiveness ** CI Confidence Interval ^ ISO: international Organization for Standardization |
I-MOVE+ NewsThank you for your interest. The I-MOVE+ project (2015-2018) is over, and this website will no longer be updated. However, activities to monitor vaccine effectiveness in Europe are ongoing and can be found on the I-MOVE and SpiDnet websites for influenza (coming soon) and pneumococcal vaccines https://sites.google.com/a/epiconcept.fr/ipd-surveillance/  |
|